Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Jun 11;311(22):2288-96.
doi: 10.1001/jama.2014.4312.

Association between intensification of metformin treatment with insulin vs sulfonylureas and cardiovascular events and all-cause mortality among patients with diabetes

Christianne L Roumie  1 , Robert A Greevy  2 , Carlos G Grijalva  3 , Adriana M Hung  1 , Xulei Liu  2 , Harvey J Murff  1 , Tom A Elasy  1 , Marie R Griffin  4
Affiliations

Association between intensification of metformin treatment with insulin vs sulfonylureas and cardiovascular events and all-cause mortality among patients with diabetes

Christianne L Roumie et al. JAMA. .

Abstract

Importance: Preferred second-line medication for diabetes treatment after metformin failure remains uncertain.

Objective: To compare time to acute myocardial infarction (AMI), stroke, or death in a cohort of metformin initiators who added insulin or a sulfonylurea.

Design, setting, and participants: Retrospective cohort constructed with national Veterans Health Administration, Medicare, and National Death Index databases. The study population comprised veterans initially treated with metformin from 2001 through 2008 who subsequently added either insulin or sulfonylurea. Propensity score matching on characteristics was performed, matching each participant who added insulin to 5 who added a sulfonylurea. Patients were followed through September 2011 for primary analyses or September 2009 for cause-of-death analyses.

Main outcomes and measures: Risk of a composite outcome of AMI, stroke hospitalization, or all-cause death was compared between therapies with marginal structural Cox proportional hazard models adjusting for baseline and time-varying demographics, medications, cholesterol level, hemoglobin A1c level, creatinine level, blood pressure, body mass index, and comorbidities.

Results: Among 178,341 metformin monotherapy patients, 2948 added insulin and 39,990 added a sulfonylurea. Propensity score matching yielded 2436 metformin + insulin and 12,180 metformin + sulfonylurea patients. At intensification, patients had received metformin for a median of 14 months (IQR, 5-30), and hemoglobin A1c level was 8.1% (IQR, 7.2%-9.9%). Median follow-up after intensification was 14 months (IQR, 6-29 months). There were 172 vs 634 events for the primary outcome among patients who added insulin vs sulfonylureas, respectively (42.7 vs 32.8 events per 1000 person-years; adjusted hazard ratio [aHR], 1.30; 95% CI, 1.07-1.58; P = .009). Acute myocardial infarction and stroke rates were statistically similar, 41 vs 229 events (10.2 and 11.9 events per 1000 person-years; aHR, 0.88; 95% CI, 0.59-1.30; P = .52), whereas all-cause death rates were 137 vs 444 events, respectively (33.7 and 22.7 events per 1000 person-years; aHR, 1.44; 95% CI, 1.15-1.79; P = .001). There were 54 vs 258 secondary outcomes: AMI, stroke hospitalizations, or cardiovascular deaths (22.8 vs 22.5 events per 1000 person-years; aHR, 0.98; 95% CI, 0.71-1.34; P = .87).

Conclusions and relevance: Among patients with diabetes who were receiving metformin, the addition of insulin vs a sulfonylurea was associated with an increased risk of a composite of nonfatal cardiovascular outcomes and all-cause mortality. These findings require further investigation to understand risks associated with insulin use in these patients.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Flow of eligible patients.
Figure 2
Figure 2
Figure 2 Panel A: Cumulative incidence of cardiovascular disease or death among propensity score matched cohort of metformin+ sulfonylurea initiators versus metformin + insulin initiators. All follow-up is through September 30, 2011 * Events are the composite of cardiovascular disease (Acute myocardial infarction, stroke) or all cause death that occurred in the 12 months between each time point. Figure 2 Panel B: Cumulative incidence of fatal and non-fatal cardiovascular events (Acute myocardial infarction, stroke or cardiovascular deaths) among propensity score matched cohort of metformin+ sulfonylurea initiators versus metformin + insulin initiators. All follow-up is through September 30, 2009 * Events are the composite of fatal and non-fatal cardiovascular events (Acute myocardial infarction, stroke or cardiovascular deaths) that occurred in the 12 months between each time point
Figure 2
Figure 2
Figure 2 Panel A: Cumulative incidence of cardiovascular disease or death among propensity score matched cohort of metformin+ sulfonylurea initiators versus metformin + insulin initiators. All follow-up is through September 30, 2011 * Events are the composite of cardiovascular disease (Acute myocardial infarction, stroke) or all cause death that occurred in the 12 months between each time point. Figure 2 Panel B: Cumulative incidence of fatal and non-fatal cardiovascular events (Acute myocardial infarction, stroke or cardiovascular deaths) among propensity score matched cohort of metformin+ sulfonylurea initiators versus metformin + insulin initiators. All follow-up is through September 30, 2009 * Events are the composite of fatal and non-fatal cardiovascular events (Acute myocardial infarction, stroke or cardiovascular deaths) that occurred in the 12 months between each time point
See this image and copyright information in PMC

Comment in

References

    1. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) Diabetes Care. 2012 Jun;35(6):1364–1379. - PMC - PubMed
    1. Weng J, Li Y, Xu W, et al. Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial. Lancet. 2008 May 24;371(9626):1753–1760. - PubMed
    1. Harrison LB, Adams-Huet B, Raskin P, Lingvay I. beta-cell function preservation after 3.5 years of intensive diabetes therapy. Diabetes Care. 2012 Jul;35(7):1406–1412. - PMC - PubMed
    1. Alvarsson M, Sundkvist G, Lager I, et al. Effects of insulin vs. glibenclamide in recently diagnosed patients with type 2 diabetes: a 4-year follow-up. Diabetes Obes Metab. 2008 May;10(5):421–429. - PubMed
    1. [Accessed November 25, 2013.];Adults with Diabetes by Diabetes Medication Status, United States, 1997–2011. Available at: http://www.cdc.gov/diabetes/statistics/meduse/fig1.htm.

Publication types

MeSH terms